FPC Rennet Patents Have Expired — So Why Hasn't a Generic Market Emerged?

The Patent on the Cheese Enzyme Expired Years Ago. So Why Does One Company Still Supply Most of the Market?

July 17, 2026July 17, 2026By Dominick Bianco, Editor-in-Chief
0
FPC Rennet Patents Have Expired — So Why Hasn't a Generic Market Emerged?
Share This:

Introduction

Almost everything written about the enzyme in 90% of North American cheese has missed the most consequential fact about it: the patents expired.

Fermentation-produced chymosin (FPC), the genetically engineered coagulant developed by Pfizer and approved by the FDA in March 1990, is not protected intellectual property. The foundational patents lapsed years ago. The technology is in the public domain. Any company with a fermentation plant and a regulatory dossier is free to manufacture it, and has been free to do so for well over a decade.

And yet the market did not open. There is no generic FPC industry. Prices did not collapse. A small number of firms — principally Novonesis of Denmark, DSM-Firmenich, and Kerry Group of Ireland — still supply the coagulant for the overwhelming majority of industrial cheese production in North America.

When a pharmaceutical patent expires, generic entrants typically drive prices down sharply within a year or two. Nothing of the kind happened here. That divergence is the story, and it has an explanation — one that is more instructive, and more troubling in its way, than the monopoly narrative currently circulating online.

Background: An Estate That Has Lapsed

The recombinant chymosin patent estate was assembled between roughly 1981 and 1993, in the first commercial wave of recombinant DNA technology. It is a crowded record. Patents covering the expression of chymosin in various microbial hosts include U.S. Patent 4,666,847, U.S. Patent 4,935,370, U.S. Patent 5,364,770, U.S. Patent 5,578,463, U.S. Patent 5,624,819, U.S. Patent 5,716,807, and U.S. Patent 5,863,759 — spanning E. coli, Bacillus subtilis, Aspergillus, Kluyveromyces lactis, and Trichoderma reesei as production organisms. That host list is itself catalogued in a later USPTO filing on chymosin production.

Pfizer’s own contribution includes U.S. Patent 5,215,908, covering the process for recovery and purification of chymosin from the fermentation broth. The production strain and purification chemistry Pfizer submitted to regulators is preserved in the WHO/JECFA monograph on chymosin from Aspergillus niger, which cites Pfizer Central Research’s 1988 submissions directly.

The relevant legal framework is patent term. Under U.S. law as it stood before the Uruguay Round Agreements Act took effect on June 8, 1995, a patent ran for 17 years from the date of grant. Applications filed after that date run 20 years from the earliest filing date.

Applying that rule to this estate places the expirations across a window running from approximately 2004 to 2015.

In simple terms: the specific technology that consumers are currently protesting — Pfizer’s original 1990 Chy-Max — has been free for anyone to copy for something on the order of fifteen years.

The Patent Treadmill

The incumbent’s answer to expiration was not to defend the old patents. It was to stop selling the old product.

Chr. Hansen — which acquired the Chy-Max line from Pfizer in October 1996, per Pfizer’s own SEC filing, and which merged with Novozymes in 2024 to form Novonesis — pursued a strategy of sequential reinvention.

Generation two: a different species.Chy-Max M, launched in the Americas in 2008 and in Europe the following year, is not bovine chymosin. It is camel chymosin, covered by WO2002036752A2 — “Method of producing non-bovine chymosin and use thereof” — filed on 6 November 2001 and co-assigned to Chr. Hansen A/S and ETH Zurich. Camel chymosin has a materially higher C/P ratio, the ratio of milk-clotting activity to general proteolytic activity, meaning it curdles milk more efficiently while degrading less of the surrounding protein. A November 2001 filing runs to approximately November 2021.

Generation three: engineered variants.Chy-Max Supreme, launched in 2019 after what the company described as five years of research, emerged from a program of site-directed mutagenesis producing chymosin variants with improved clotting specificity. The relevant filings include WO2013174840A1, WO2016207214A1, WO2016128476A1 (covering blends), U.S. Patent 9,930,899 (granted 2018), U.S. Patent 10,779,552 (granted 2020), and U.S. Patent 10,941,389. Twenty years from filing places these in the range of 2033 into the late 2030s.

Each generation goes off-patent. By the time it does, the successor is already in the market and protected.

It is worth being precise about what this is and is not. In pharmaceuticals, “evergreening” is a pejorative describing trivial reformulations that extend monopoly without therapeutic benefit. That is not an accurate description here. The improvements are substantive and measurable: Chr. Hansen has stated that its newest generation can increase cheese yield by up to 1% from the same volume of milk — which, applied across global production, the company calculated at more than 220 million kilograms of additional cheese. These are real innovations, lawfully protected. That is what the patent system is designed to reward.

But the market effect is the same as evergreening regardless of intent. A generic manufacturer entering today would be selling the 1990 product into a market where every serious buyer has moved to the 2019 product.

Why No Generic Market Emerged

The absence of generic entry is not explained by patents. It is explained by sunk costs — and here the relevant framework is not antitrust doctrine but contestable markets theory, developed by William Baumol, John Panzar and Robert Willig in the early 1980s.

The core insight of that theory is that market concentration, by itself, tells you almost nothing. What determines whether an incumbent can be disciplined is whether entry and exit are cheap. A market with one firm can behave competitively if a rival could enter costlessly and leave without losses. A market with several firms can behave like a monopoly if entry requires unrecoverable investment.

FPC production is close to the second case, for four reasons:

  1. Capital intensity. Industrial-scale fermentation, downstream separation and purification infrastructure is expensive and largely unrecoverable if the venture fails.
  2. Regulatory approval is per-jurisdiction. A new coagulant requires a dossier and clearance in every market where the resulting cheese will be sold — slow, costly, and repeated country by country.
  3. Customer switching costs. A cheese plant that changes coagulant must requalify its process. Coagulant choice affects curd firmness, cutting time, moisture retention and ripening. Getting it wrong destroys batches at industrial volume. Processors are structurally reluctant to switch, and reluctant to switch to a smaller supplier in particular.
  4. A moving target. Even a successful generic entrant faces an incumbent that has already launched a measurably better product and holds patents on it into the 2030s.

In simple terms: the barrier is not the law. It is the cost of building the plant, clearing the regulators, and persuading a cheesemaker to bet a production line on you.

Evidence of Genuine Competition

The patent record also contains something the monopoly narrative cannot accommodate: proof of an active R&D race.

DSM’s WO2013/164479A2 covers its own bovine chymosin mutants. And DSM’s filings go further — its published application US2015/0140169A1 describes side-by-side Cheddar trials at the DSM Biotechnology Center in Delft, benchmarking its variants directly against both its own Maxiren product and Chr. Hansen’s Chy-Max M, and reporting that one variant achieved comparable coagulation at a 20% lower dosage.

The competition has also been adversarial. Public patent records for the WO2013174840A1 family indicate worldwide family litigation first filed in February 2020 — these variant patents have been contested in court, not merely filed.

Two firms engineering competing enzymes, each citing the other’s patents, each running comparative pilot production, and litigating the results, is not the signature of a monopoly. It is the signature of an oligopoly competing hard on product performance.

That is consistent with the merger record. When Novozymes and Chr. Hansen combined in a roughly $22 billion transaction, competition authorities in four jurisdictions — the European Commission, the U.S. Federal Trade Commission, China’s SAMR and Brazil’s CADE, per the deal record — reviewed the transaction. The Commission required exactly one remedy, and it concerned lactase, not coagulants: a divestiture sold to Kerry Group for approximately €150 million under independent trustee supervision. The coagulant portfolio was cleared without conditions.

Analysis: The Gap Nobody’s Law Covers

Put the pieces together and a structural gap appears.

Patent law asks whether an invention is novel and non-obvious. Chr. Hansen’s camel chymosin and engineered variants plainly are. The system worked as designed and granted protection.

Merger control asks whether a specific transaction makes competition worse. Because Novozymes was not a meaningful coagulant competitor, the merger did not increase concentration in coagulants — so no remedy was warranted. The system worked as designed and cleared it.

Neither body of law asks the question a citizen would actually ask: is this market contestable? Is there any realistic path by which a new supplier could discipline the incumbent on price?

Merger control cannot reach pre-existing concentration; it only polices changes to it. Patent law cannot reach a firm that keeps genuinely innovating. A market can therefore remain durably concentrated — with an essential food input, no legal monopoly, no wrongdoing by anyone, and no regulator with jurisdiction over the outcome.

There is a further problem: no public data exists on coagulant market shares. Neither the firms nor the competition authorities publish them. Any serious assessment of concentration in this sector is currently impossible for an outside party to perform. That absence of information is not an oversight to be shrugged at; it is the precondition that keeps the question unaskable.

Impact

For cheesemakers, the practical consequence is dependency. The input that makes industrial cheese possible comes from a handful of firms, none of them North American, on terms no buyer can benchmark against a generic alternative that does not exist.

For consumers, the consequence is invisible, because coagulant is a fraction of a cent per pound of cheese. Nobody is being gouged at the supermarket. The exposure is not price — it is supply concentration in a critical input, of exactly the kind policymakers now routinely map for semiconductors, rare earths and pharmaceutical precursors, and almost never map for food enzymes.

Conclusion

The viral version of this story asks the wrong question. It asks who owns the patent, and the answer turns out to be: nobody owns the one that matters, and hasn’t for years.

The better question is why a public-domain technology, essential to a multibillion-dollar American food category, produced no domestic industry and no generic competition. The answer is not conspiracy and not illegality. It is sunk costs, regulatory friction, switching risk, and an incumbent that has out-innovated the expiration of its own monopoly — lawfully, and in plain view.

That is a harder story to tell than a villain. It is also the true one.

Key Takeaways

  • The foundational FPC patents have expired. The estate — including U.S. Patents 4,666,847, 4,935,370, 5,215,908, 5,364,770, 5,578,463, 5,624,819, 5,716,807 and 5,863,759 — was filed 1981–1993 and lapsed between roughly 2004 and 2015.
  • Patents filed before June 8, 1995 ran 17 years from grant; later filings run 20 years from filing (Uruguay Round Agreements Act).
  • Pfizer’s original Chy-Max is public domain. Anyone may manufacture it. No one meaningfully does.
  • The incumbent stayed ahead by replacing the product, not defending the patent: bovine chymosin (1990) → camel chymosin, Chy-Max M (WO2002036752A2, filed 6 Nov 2001 with ETH Zurich) → engineered variants, Chy-Max Supreme (2013–2016 filings, protected to roughly 2033–2039).
  • The improvements are substantive, not sham — up to 1% higher cheese yield, over 220 million kg globally by the company’s own calculation.
  • No generic market emerged — explained by sunk costs, per-jurisdiction regulatory approval, cheese-plant requalification risk, and a moving product target. Contestable markets theory (Baumol, Panzar, Willig), not patent law, is the operative framework.
  • Real competition exists.DSM’s patent filings benchmark its variants against Chy-Max M in side-by-side Cheddar trials at Delft, reporting comparable coagulation at 20% lower dosage. The variant patent family has been litigated since 2020.
  • The structural gap: patent law asks if an invention is novel. Merger control asks if a deal worsens competition. Neither asks whether the market is contestable.
  • No public coagulant market-share data exists — the single most fixable problem identified in this reporting.

Sources

Primary — patent record

Primary — corporate and regulatory filings

Secondary

Editor’s note on patent dates: Expiration ranges in this article are derived from filing and grant dates applied against standard statutory patent terms. Actual expiration can be affected by term adjustments, extensions, terminal disclaimers and maintenance-fee status, and varies by jurisdiction. NexfinityNews states the structure of the patent estate with confidence and the specific dates as approximations.

Share This: